Table 1 Selected PARP-1 inhibitors in development
Company | Product | Status | Indication |
|---|---|---|---|
Inotek Pharmaceuticals (Beverly, Massachusetts) | INO-1001 | Phase 2 | Cardiovascular indications |
Pfizer (New York) | AG014699 | Phase 2 | Malignant melanoma |
Inotek/Genentech (S. San Francisco) | INO-1001 | Phase 1b | Malignant melanoma |
BiPar Sciences (Brisbane, California) | BS-201 | Phase 1 | Cancer |
AstraZeneca (London) | AZD2281 | Phase 1 | Breast cancer |
BiPar Sciences | BS-401 | Preclinical | Pancreatic cancer |
MGI Pharma (Bloomington, Minnesota) | n/a | Preclinical | Radiation/ chemotherapy sensitizer |
CS | |||
